Based on the implications of this initial signal, future studies should focus on larger cohorts, in-person examination of individuals with Fabry disease by a movement disorders neurologist, and related biomarker studies including alpha-galactosidase A activity and GLA mutation analysis. The gene discussed is GLA; the disease is movement disorder.